These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 31185985)

  • 21. A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update.
    Thomopoulou K; Tzardi M; Mavroudis D; Souglakos I
    Case Rep Oncol Med; 2019; 2019():4767019. PubMed ID: 30911424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erratum: Regorafenib in Patients With Solid Tumors With
    JCO Precis Oncol; 2024 Apr; 8():e2400121. PubMed ID: 38603653
    [No Abstract]   [Full Text] [Related]  

  • 23. Regorafenib-induced Myopathy.
    Ochiai S; Ueno T; Igarashi S; Arai A
    Intern Med; 2024 Jan; ():. PubMed ID: 38220194
    [No Abstract]   [Full Text] [Related]  

  • 24. Regorafenib in Patients With Solid Tumors With
    Sahai V; Rothe M; Mangat PK; Garrett-Mayer E; Suhag V; Dib EG; Mehmi I; Kadakia KC; Pisick E; Duvivier HL; Le P; Li R; Michelin DP; Wilcox RE; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2024 Apr; 8():e2300527. PubMed ID: 38603652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting All
    Bhamidipati D; Pellatt A; Subbiah V
    JCO Precis Oncol; 2024 Feb; 8():e2300670. PubMed ID: 38380848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study.
    Nakashima M; Li K; Chen Q; de Silva S; Li H; Kawakami K; Wei Q; Luo S; Zhao H
    BMC Cancer; 2023 Dec; 23(1):1268. PubMed ID: 38129822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
    Guerrero RM; Labajos VA; Ballena SL; Macha CA; Lezama MS; Roman CP; Beltran PM; Torrejon AF
    Ecancermedicalscience; 2022; 16():1489. PubMed ID: 36819812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Promising Role of TGF-β Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report.
    De Summa S; Danza K; Pilato B; Matera G; Fasano R; Calabrese A; Lacalamita R; Silvestris N; Tommasi S; Argentiero A; Brunetti O
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer.
    Li H; Fu G; Wei W; Huang Y; Wang Z; Liang T; Tian S; Chen H; Zhang W
    Front Oncol; 2020; 10():595107. PubMed ID: 33312954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.
    Marin JJG; Macias RIR; Monte MJ; Herraez E; Peleteiro-Vigil A; Blas BS; Sanchon-Sanchez P; Temprano AG; Espinosa-Escudero RA; Lozano E; Briz O; Romero MR
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32933095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review.
    Brunetti O; Calabrese A; Palermo L; Solimando AG; Argentiero A
    Clin Case Rep; 2019 Dec; 7(12):2379-2383. PubMed ID: 31893063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
    Al-Marrawi MY; Saroya BS; Brennan MC; Yang Z; Dykes TM; El-Deiry WS
    Cancer Biol Ther; 2013 Aug; 14(8):703-10. PubMed ID: 23792568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
    Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
    Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
    Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
    BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.